Table 2 Summary of clinically approved VEGFR inhibitors

Sorafenib (1)

VEGFR2/3, PDGFRβ, c-Kit, BRAF

Advances renal cell carcinoma, hepatocellular carcinoma

2007

II

[25]

Sunitinib (2)

VEGFR1/2, PDGFRβ, FLT3

Renal cell carcinoma, gastrointestinal stromal tumors

2006

I

[26]

Pazopanib (3)

VEGFR2, PDGFRβ, c-Kit

Hepatocellular carcinoma

2012

I

[27]

Vandetanib (4)

VEGFR2/3, EGFR, RET

Late-stage metastatic medullary

thyroid tumor

2011

I

[28]

Axitinib (5)

VEGFR1/2, c-Kit

Renal cell carcinoma

2012

I

[29]

Carbozantinib (6)

VEGFR2, c-Met, RET

Thyroid tumor

2012

II

[30]

Lenvatinib (7)

VEGFR1/2/3

Thyroid tumor

2015

II

[31]

Regorafenib (8)

VEGFR1/2/3, PDGFRβ, c-Kit, BRAF

Colorectal tumor, advanced GI

stromal cancer, hepatocellular carcinoma

2015

II

[32]

Ponatinib (9)

Abl, PDGFRα, VEGFR2, FGFR1, Src

Chronic myeloid leukemia, acute

lymphoblastic leukemia

2012

I

[33]

Lucitanib (10)

VEGFR1/2/3, FGFR-1,

FGFR-2

Metastatic breast tumor

Phase II clinical trials

II

[34]

Motesanib (11)

VEGFR1/2/3

Non-small-cell lung tumor

Phase III clinical trials

I

[35]

Vatalanib (12)

VEGFR1/2/3, PDGFRβ, c-Kit

Colorectal tumor

Phase III clinical trials

III

[36]